ImmuCell Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	29.93	27.64	26.49	17.47	18.57	19.24
Revenue Growth (YoY)	9.64%	4.35%	51.63%	-5.90%	-3.51%	25.42%
Cost of Revenue	17.19	16.2	18.55	13.6	10.92	10.59
Gross Profit	12.75	11.45	7.94	3.87	7.65	8.66
Selling, General & Admin	7.64	6.75	5.68	5.22	5.45	4.23
Research & Development	2.6	3.04	3.9	4.39	4.49	4.17
Total Operating Expenses	10.25	9.8	9.58	9.62	9.95	8.4
Operating Income	2.5	1.65	-1.64	-5.75	-2.3	0.26
Total Non-Operating Income (Expense)	-3.02	-2.68	-0.51	-0.02	-0.19	-0.33
Pretax Income	-0.52	-1.03	-2.15	-5.77	-2.49	-0.07
Provision for Income Taxes	0.02	0.01	0.01	0	0.01	0.01
Net Income	-0.55	-1.04	-2.16	-5.77	-2.49	-0.08
Net Income to Common	-0.55	-1.04	-2.16	-5.77	-2.49	-0.08
Shares Outstanding (Basic)	9	9	8	8	8	8
Shares Outstanding (Diluted)	9	9	8	8	8	8
Shares Change (YoY)	6.73%	10.52%	5.42%	0.03%	2.01%	5.25%
EPS (Basic)	-0.07	-0.12	-0.26	-0.75	-0.32	-0.01
EPS (Diluted)	-0.07	-0.12	-0.26	-0.75	-0.32	-0.01
Shares Outstanding	9.05	9.05	8.98	7.75	7.75	7.74
Free Cash Flow	3.38	1.22	-0.11	-6.57	-5.52	-1.65
Free Cash Flow Growth	175.62%	-	-	-	-	-
Free Cash Flow Per Share	0.37	0.14	-0.01	-0.85	-0.71	-0.22
Gross Margin	42.59%	41.40%	29.97%	22.15%	41.19%	44.98%
Operating Margin	8.16%	5.97%	-6.19%	-32.90%	-12.38%	1.34%
Profit Margin	-1.82%	-3.76%	-8.14%	-33.05%	-13.43%	-0.41%
FCF Margin	11.28%	4.43%	-0.41%	-37.59%	-29.72%	-8.60%
EBITDA	5.02	4.38	1.05	-3.03	0.19	2.72
EBITDA Margin	16.79%	15.84%	3.95%	-17.35%	1.02%	14.13%
EBIT	2.5	1.65	-1.64	-5.75	-2.3	0.26
EBIT Margin	8.16%	5.97%	-6.19%	-32.90%	-12.38%	1.34%
Effective Tax Rate	-4.24%	-1.12%	-0.47%	-0.08%	-0.31%	-13.26%

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q